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Figure 1. Kaplan-Meier analysis of OS
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(range 13 e 79), were included. The most common induction
chemotherapy used was IA 3+7 (idarubicin 12mg/m2/day for
3 days and cytarabine 100mg/m2/day for 7 days), received by
98.7% of patients during ﬁrst induction and 70% of patients
during re-induction. Overall CR rate was 80.1%, with 62.7%
and 15.6% of patients attaining CR after one and two cycles of
induction chemotherapy respectively. In addition, relapse
rates were similar in patients who achieved CR after one and
two cycles of induction chemotherapy (42.4% vs. 40.9%,
p¼0.94). Of note, among patients requiring re-induction,
there was no signiﬁcant difference in the CR rates between
the use of IA 3+7 and non-IA 3+7 regimen (p¼0.45). About
10% (n¼39) of patients had primary resistant AML, of which
seven of them achieved CR with salvage chemotherapy and
six relapsed later.
Multivariate analysis identiﬁed Malay race (OR: 18.6, 95%
CI 3.3 e 105.4) and patients with adverse risks (OR: 17.2, 95%
CI 3.1 e 97.3), deﬁned by the European Leukemia Net (ELN)
risk classiﬁcation, as predictors for primary resistant AML.
However, Malay race was not found to have a higher inci-
dence of adverse risks compared to non-Malay (p¼0.98).
Conclusion: Themost signiﬁcant ﬁnding from this studywas
that Malay race is associated with primary treatment resis-
tance to conventional induction chemotherapy. Further
studies may be warranted to identify other contributing
factors and optimize induction treatment for this subgroup
of patients.Figure 1. FIC50 of A) BU, B) MEL, C) FLU, D) C244
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Introduction: Busulfan (BU), melphalan (MEL), ﬂudarabine
(FLU), clofarabine (CLO), cytosine arabinoside (Ara-C), and
etoposide (VP-16) are widely used as conditioning re-
gimens for hematopoietic stem cell transplant (HSCT) for
myeloid and/or lymphoid malignancies. Among these
agents, BU has been used more often for patients with
myeloid malignancies. To show the priorities or inferiorities
of anti-tumor activities of both myeloid and lymphoid
leukemia cells in vitro, cytotoxicities of these 6 compounds
were compared between human myeloid and lymphoid
leukemia cell lines.
Materials and methods: The following human cell lines
were exposed to all 6 chemotherapeutic agents: promye-
locytic leukemia cell HL60; chronic myelogenous leukemia
cell K562; acute myelogenous leukemia cell KU-812; acute
monocytic leukemia cell THP-1; acute lymphoblastic leu-
kemia cells CCRF-CEM, MOLT-3, and MOLT-4; lympho-
blastoid cell WIL2-NS. Each cell line was exposed to each
agent for 72 hours at 4 digits varied concentrations in 96
well micro plate with triplicate wells containing 5,000 cells
in each well. Cell viabilities were determined by adding
WST-8 (Kishida Chemical Co., Ltd.) to each well and
reading absorbance of 450 nm wave length using multi
micro plate reader GloMax-Multi+ Detection System
(Promega KK).
The drug concentration capable of 50% growth inhibitory
concentration (IC50) was calculated using GraphPad Prism 6
(GraphPad Software, Inc.).
Results: The anti-tumor activities of these 6 chemothera-
peutic agents for both myeloid and lymphoid leukemia cell
lines were determined as IC50. K562 was resistant to all the
agents having the highest IC50 in all agents (high than 100,LO, E) Ara-C, and F) VP-16 for myeloid.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S185eS205 S189101, 529, 0.46, higher than 10 and 11.7 micro M for BU, MEL,
FLU, CLO, Ara-C and VP-16) and MOLT-4 was relatively sen-
sitive to tested agents showing lowest or lower IC50 than
those of other cell lines (14.2, 0.89, 0.28, 0.021, 0.0044 and
0.017 micro M respectively).
BU, MEL, FLU, CLO and Ara-C showed similar activities
against myeloid leukemia cells and lymphoid leukemia cells
[Fig 1 A)-E)]. On the other hand, VP-16 showed more anti-
leukemia activities against lymphoid leukemia cells than
myeloid leukemia cells [Fig 1 F)].
Conclusion: Although the number of tested cell lines is
limited, BU showed similar anti-leukemic activities against
myeloid and lymphoid leukemia cell lines as is shown byMEL,
FLU, CLO, and Ara-C. This data supports the use of busulfan as
a preparative agent in patients with lymphoid malignancies.
Further studies including combination of multiple chemo-
therapeutic agents would show more advanced scientiﬁc
rationale for strategic conditioning regimen of HSCT for
leukemia.245
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Acute myeloid leukemia/Myelodysplastic syndrome (AML/
MDS) is highly heterogeneous disease and prediction ofTable 1
Patient Characteristics N (%)
Number (AML/MDS) 54 (48/6)
Median Age (Range), years 56.5 (33-73)
Status at Transplant
CR1 (Complete remission -1) 32 (59%)
CR2 (Complete remission -2) 2 (4%)
P1F, REL (primary refractory, Relapse) 20 (37%)
Donor Source
Matched Related Donor 13 (24%)
Mismatched related Donor 1 (2%)
Matched Unrelated Donor 35 (65%)
Mismatched Unrelated Donor 3 (5%)
Haplo-Identical 2 (4%)
C1BMTR Risk
High 17 (31%)
Intermediate 2 (4%)
Low 35 (65%)
Cytogenetics Risk
High 30 (55%)
Low 24 (45%)
Conditioning Regimen Intensity
FtC (Full Intensity) 37 (69%)
RIC( Reduced Intensity) 17 (31%)
Conditioning Regimen
FluBU4 35 (65%)
FLuBU-PTCY 2(4%)
FluBU2 16 (29%)
CyTBI (Cytoxan/TBI) 1(2%)
Chimerism at Day 30
>95% 51 (94%)
<90% 3 (6%)
CD34 Infused X million/Kg (Range) 2.37-16
Median (million/Kg) 5.96
Median to WBC engraftment 12
Median to Plat engraftment 18
Figure 1.relapse at the molecular level is a challenging task post
allogeneic HCT. Signiﬁcant existing data supports the MCP-1/
CCR2 axis expression in the majority of AML blasts and it has
been shown to be involved in blasts trafﬁcking and prolif-
eration. To evaluate the role of MCP-1 in prediction of AML/
MDS relapse post allogeneic HCT, we measured the serum
values of MCP-1 at day 30 post HCT in 54 consecutive pa-
tients with AML/MDS using multiple luminex ELISA assay.
The samples were collected from the patients prospectively
Results: Patient characteristics are shown in Table 1.
Median age at transplant was 56 year old. GVHD
prophylaxis was Tacrolimus/Methotrexate for FIC and
Tacrolimus/ Mycophenolate for RIC. Thymoglobulin was
added at dose of 4.5 mg/Kg total dose for matched
unrelated donor recipients. All the patients engrafted with
no graft failure. Full chimerism at day 30 (> 95%) was
achieved in 51/54 patients supported by morphological
evidence of complete remission. With median follow up of
17 months, overall survival at 1 & 2 years was 78% and 67%.
Cumulative incidence of relapse at 1 year was 31% +/- 6%
while cumulative incidence of treatment related mortality
(TRM) at 2 years was 10% +/- 4%. In order to evaluate the
impact of MCP-1 levels at day 30 post HCT in predicting
relapse, patients with less than 95% chimerism (n¼3) and
patients who died as result of TRM prior to relapse (n¼5)
were excluded from the analysis. At day 30 post HCT,
patients with full chimerism who relapsed (n¼13) had
higher mean MCP-1 level of 514 +/- 175 versus patients
with full chimerism who did not relapse (n¼33), mean
MCP-1 level of 382 +/-181; P¼ 0.03. (Figure 1). The median
